Literature DB >> 508553

Pharmacokinetics of metoclopramide intravenously and orally determined by liquid chromatography.

C Graffner, P O Lagerström, P Lundborg, O Rönn.   

Abstract

1 A rapid and sensitive method, based on liquid chromatography, has been developed for determination of metoclopramide concentrations in plasma and urine samples. Concentrations down to 15 nmol/1 (5 ng/ml) of plasma and 100 nmol/1 (30 ng/ml) of urine could be determined with a relative standard deviation of less than or equal to 10%. The method was used to study disposition of metoclopramide in healthy volunteers following single doses intravenously and orally as aqueous solution and a slow release tablet. 2 The initial distribution after intravenous administration was very rapid. The elimination half-life postdistribution was 4.9 h. The apparent volume of distribution, Vd, was 3.0 1/kg body weight. On average 19% was excreted unchanged after intravenous administration of 5 and 10 mg (15 and 30 mumol) of drug. The rate of absorption of metoclopramide was delayed after administration of a slow release tablet and the maximum plasma concentration was about 50% lower than after a solution. The extent of bioavailability was the same following the two different formulations suggesting a first-pass elimination of 25-40%.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 508553      PMCID: PMC1429814          DOI: 10.1111/j.1365-2125.1979.tb01028.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates.

Authors:  A J Sedman; J G Wagner
Journal:  J Pharm Sci       Date:  1976-07       Impact factor: 3.534

2.  Pharmacokinetic and concentration-effect studies with metoclopramide [proceedings].

Authors:  D N Bateman; D S Davies; C Kahn; K Mashiter
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

3.  The absorption and elimination of metoclopramide in three animal species.

Authors:  O M Bakke; J Segura
Journal:  J Pharm Pharmacol       Date:  1976-01       Impact factor: 3.765

4.  Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion.

Authors:  J C Loo; S Riegelman
Journal:  J Pharm Sci       Date:  1970-01       Impact factor: 3.534

5.  Pharmacokinetics of metoclopramide.

Authors:  D N Bateman; D S Davies
Journal:  Lancet       Date:  1979-01-20       Impact factor: 79.321

6.  Tardive dyskinesia associated with metoclopramide.

Authors:  S Lavy; E Melamed; S Penchas
Journal:  Br Med J       Date:  1978-01-14

7.  Metoclopramide metabolism and determination by high-pressure liquid chromatography.

Authors:  L Teng; R B Bruce; L K Dunning
Journal:  J Pharm Sci       Date:  1977-11       Impact factor: 3.534

8.  Pharmacokinetic and concentration-effect studies with intravenous metoclopramide.

Authors:  D N Bateman; C Kahn; K Mashiter; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

Review 9.  Metoclopramide: a review of its pharmacological properties and clinical use.

Authors:  R M Pinder; R N Brogden; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

10.  The effect of oral and intravenous metoclopramide on human lower esophageal sphincter pressure.

Authors:  S Cohen; D W Morris; H J Schoen; A J DiMarino
Journal:  Gastroenterology       Date:  1976-04       Impact factor: 22.682

  10 in total
  27 in total

Review 1.  Risks and benefits of drugs used in the management of postoperative nausea and vomiting.

Authors:  Y F Sung
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

3.  Bioavailability of intranasal metoclopramide.

Authors:  M J Ward; D C Buss; J Ellershaw; A Nash; P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

4.  Antiemetic effect and pharmacokinetics of high dose metoclopramide in cancer patients treated with cisplatin-containing chemotherapy regimens.

Authors:  H Havsteen; H Nielsen; M Kjaer
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Pharmacokinetic studies of high-dose metoclopramide with and without forced diuresis.

Authors:  C Ell; J Braun; H J König; S Domschke; W Domschke
Journal:  Klin Wochenschr       Date:  1985-06-18

6.  Preliminary studies of the pharmacokinetics and pharmacodynamics of prochlorperazine in healthy volunteers.

Authors:  W B Taylor; D N Bateman
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

7.  Continuous infusion of high-dose metoclopramide for the prevention of nausea and vomiting in patients receiving cancer chemotherapy.

Authors:  R A Joss; R L Galeazzi; K W Brunner
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 8.  Pharmacokinetics of high-dose metoclopramide in cancer patients.

Authors:  E M McGovern; J Grevel; S M Bryson
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

9.  Metoclopramide and breast feeding: transfer into milk and the newborn.

Authors:  A Kauppila; P Arvela; M Koivisto; S Kivinen; O Ylikorkala; O Pelkonen
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

10.  Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid.

Authors:  R A Tokola; P J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.